Catalent IncNYSE:CTLT
- LAST PRICE97.9500
- TODAY'S CHANGE (%)-1.7800 (-1.7848%)
- Bid / Lots97.8700/ 1
- Ask / Lots97.9800/ 2
- Open / Previous Close101.0300 / 99.7300
- Day Range
- 52 Week Range
- Volume247,655
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CTLT |
|---|---|---|
| 09:32 ET | 24105 | 100.35 |
| 09:34 ET | 7916 | 101.54 |
| 09:36 ET | 600 | 101.195 |
| 09:38 ET | 499 | 101.07 |
| 09:39 ET | 1001 | 100.595 |
| 09:41 ET | 3320 | 100.4775 |
| 09:43 ET | 300 | 100.87 |
| 09:45 ET | 1902 | 100.82 |
| 09:48 ET | 900 | 100.65 |
| 09:50 ET | 300 | 100.46 |
| 09:52 ET | 700 | 100.42 |
| 09:54 ET | 500 | 100.605 |
| 09:56 ET | 4139 | 100.64 |
| 09:57 ET | 1109 | 100.685 |
| 09:59 ET | 1600 | 101.22 |
| 10:01 ET | 700 | 101.38 |
| 10:03 ET | 839 | 101.23 |
| 10:06 ET | 1762 | 101.2 |
| 10:08 ET | 800 | 101.23 |
| 10:12 ET | 300 | 100.975 |
| 10:14 ET | 3579 | 100.75 |
| 10:15 ET | 2651 | 100.75 |
| 10:19 ET | 720 | 100.525 |
| 10:21 ET | 897 | 100.32 |
| 10:24 ET | 1117 | 100.315 |
| 10:26 ET | 308 | 100.26 |
| 10:28 ET | 2202 | 100.545 |
| 10:30 ET | 567 | 100.83 |
| 10:32 ET | 2804 | 100.96 |
| 10:33 ET | 1100 | 100.955 |
| 10:35 ET | 748 | 100.76 |
| 10:37 ET | 1053 | 100.45 |
| 10:39 ET | 1100 | 100.33 |
| 10:42 ET | 1116 | 100.33 |
| 10:44 ET | 300 | 100.47 |
| 10:46 ET | 1400 | 100.2 |
| 10:48 ET | 900 | 100.091 |
| 10:50 ET | 698 | 100.161 |
| 10:51 ET | 1012 | 100.16 |
| 10:53 ET | 10900 | 100.09 |
| 10:55 ET | 1725 | 100.1 |
| 10:57 ET | 1100 | 99.905 |
| 11:00 ET | 400 | 99.7 |
| 11:02 ET | 432 | 99.63 |
| 11:04 ET | 500 | 99.56 |
| 11:06 ET | 1500 | 99.565 |
| 11:08 ET | 1002 | 99.33 |
| 11:09 ET | 1500 | 99.35 |
| 11:11 ET | 430 | 99.24 |
| 11:13 ET | 401 | 99.11 |
| 11:15 ET | 400 | 99.14 |
| 11:18 ET | 900 | 98.981 |
| 11:20 ET | 1153 | 98.9627 |
| 11:22 ET | 500 | 98.87 |
| 11:24 ET | 1215 | 98.865 |
| 11:26 ET | 1155 | 98.91 |
| 11:27 ET | 2728 | 98.9927 |
| 11:29 ET | 400 | 98.87 |
| 11:31 ET | 2463 | 99.075 |
| 11:33 ET | 500 | 98.9 |
| 11:36 ET | 1145 | 98.89 |
| 11:38 ET | 700 | 98.845 |
| 11:40 ET | 2387 | 98.79 |
| 11:42 ET | 1500 | 98.75 |
| 11:44 ET | 701 | 98.75 |
| 11:45 ET | 2582 | 98.76 |
| 11:47 ET | 577 | 98.9303 |
| 11:49 ET | 1400 | 98.87 |
| 11:51 ET | 1247 | 98.865 |
| 11:54 ET | 2101 | 98.81 |
| 11:58 ET | 2407 | 98.46 |
| 12:00 ET | 1303 | 98.46 |
| 12:03 ET | 3744 | 98.24 |
| 12:05 ET | 300 | 98.185 |
| 12:07 ET | 1167 | 98.295 |
| 12:09 ET | 974 | 98.08 |
| 12:12 ET | 1800 | 97.82 |
| 12:14 ET | 921 | 98.08 |
| 12:16 ET | 2130 | 98.06 |
| 12:18 ET | 1276 | 98.08 |
| 12:20 ET | 1004 | 98.17 |
| 12:21 ET | 600 | 98.25 |
| 12:23 ET | 1501 | 98.445 |
| 12:25 ET | 1102 | 98.31 |
| 12:27 ET | 803 | 98.23 |
| 12:30 ET | 788 | 98.26 |
| 12:32 ET | 1651 | 98.24 |
| 12:34 ET | 1800 | 98.29 |
| 12:36 ET | 800 | 98.19 |
| 12:38 ET | 720 | 98.15 |
| 12:39 ET | 1994 | 98.05 |
| 12:41 ET | 400 | 97.855 |
| 12:43 ET | 1790 | 97.79 |
| 12:45 ET | 982 | 97.78 |
| 12:48 ET | 475 | 97.695 |
| 12:50 ET | 1977 | 97.985 |
| 12:52 ET | 500 | 98.02 |
| 12:54 ET | 1750 | 97.94 |
| 12:56 ET | 4474 | 98.045 |
| 12:57 ET | 760 | 98.12 |
| 12:59 ET | 1900 | 97.95 |
May 16, 2022
BRIEF-Third Point Dissolves Share Stake In Accenture & Disney, Cuts Share Stake In Catalent , from 5:30PM ET on Monday May 16, 2022 by Thomson Reuters
5:30PM ET on Monday May 16, 2022 by Thomson Reuters
May 9, 2022
Europe launches first SPAC focused on production of complex drugs, from 3:07AM ET on Monday May 09, 2022 by Thomson Reuters
3:07AM ET on Monday May 09, 2022 by Thomson Reuters
May 4, 2022
--Morgan Stanley Adjusts Catalent's Price Target to $132 from $145, Keeps Overweight Rating, from 12:52PM ET on Wednesday May 04, 2022 by MT Newswires
12:52PM ET on Wednesday May 04, 2022 by MT Newswires--UBS Adjusts Catalent Price Target to $145 From $155, Maintains Buy Rating, from 12:51PM ET on Wednesday May 04, 2022 by MT Newswires
12:51PM ET on Wednesday May 04, 2022 by MT Newswires--KeyBanc Adjusts Catalent's Price Target to $125 From $155, Keeps Overweight Rating, from 7:14AM ET on Wednesday May 04, 2022 by MT Newswires
7:14AM ET on Wednesday May 04, 2022 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Catalent Inc | 17.5B | 35.3x | +28.57% |
Incyte Corp | 16.3B | 17.5x | +51.40% |
Horizon Therapeutics PLC | 20.3B | 24.3x | --- |
Jazz Pharmaceuticals PLC | 9.2B | -19.5x | --- |
Perrigo Company PLC | 5.0B | -37.3x | --- |
Novo Nordisk A/S | 183.5B | 35.3x | +6.74% |
Company Information
Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.
Contact Information
- Headquarters
- 14 Schoolhouse RdSOMERSET, NJ, United States 08873-1213
- Phone
- 732-537-6200
- Fax
- 732-537-6480
Executives
- Executive Chairman of the Board
- John Chiminski
- President, Chief Executive Officer, Director
- Alessandro Maselli
- Chief Financial Officer, Senior Vice President
- Thomas Castellano
- President - Oral & Specialty Delivery
- Jonathan Arnold
- President - Biologics and Chief Commercial Officer
- Karen Flynn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.5B |
|---|---|
Revenue (TTM) | $4.7B |
Shares Outstanding | 179.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.37 |
EPS | $2.78 |
Book Value | $25.07 |
P/E Ratio | 35.3x |
Price/Sales (TTM) | 3.7 |
Price/Cash Flow (TTM) | 20.9x |
Operating Margin | 16.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
